Learn more about investing in BrickBuilt Therapeutics

Our team will get back to you soon to follow up on your inquiry.
Opt-In Checkbox
BrickBuilt Therapeutics
Microbiome-based therapeutics.
Funding to Date*
* Data source: Crunchbase
Brian A. Klein, Ph.D, CEO
If we could address diseases of the mouth in a more precise way, we would have less downstream systemic problems.
Half the world's population suffers from some sort of oral disease.

Oral diseases are systemic diseases suffered by over 3.5 billion people worldwide: the periodontal disease suffered by half of American adults is linked to diseases such as heart disease, stroke, diabetes and obesity. BrickBuilt Therapeutics is developing a live biological product discovered by CEO Brian Klein. BrickBuilt is using this strain and others in its microbial library to develop microbiome-focused therapeutics for oral and systemic diseases.

This is not a single asset company: BrickBuilt scientists have built a platform to screen the world’s first purpose-built oral microbial culture collection to identify bacterial strains which have therapeutic merit.